We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Pfizer, Salesforce, ADP, General Motors and Southwest Airlines
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 6, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Pfizer (PFE - Free Report) , Salesforce (CRM - Free Report) , ADP (ADP - Free Report) , General Motors (GM - Free Report) and Southwest Airlines (LUV - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Pfizer, Salesforce and ADP
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer, Salesforce and ADP. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Pfizer’s shares have outperformed the peer group year-to-date (the stock is up +14.2% over this period vs. a +3.8% increase for the Zacks Large-Cap Pharmaceuticals industry). Pfizer has been working on strengthening its product portfolio through acquisitions and licensing deals.
However, Pfizer is facing top-line headwinds in the form of genericization of key drugs, supply challenges in the legacy Hospira portfolio, pricing pressure and rising competition. Nonetheless, the Zacks analyst thinks new products like Ibrance, contribution from acquisitions, cost-cutting efforts, a lower tax rate and share buybacks should help the company achieve its guidance.
Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals through 2022, including around 15 products that have blockbuster potential. Pfizer’s growing immuno-oncology portfolio has strong potential. Bavencio is being considered a key long-term growth driver for Pfizer. In oncology, Pfizer has four potential medicines under FDA’s priority review.
Shares of Strong-Buy ranked Salesforce have handily beaten the broader Tech sector over the past year, with the stock up nearly three times the Zacks Technology sector's +20.2% gain. Salesforce reported stellar Q2 results and provided a strong outlook.
The Zacks analyst thinks the company’s diverse cloud offerings and strong spending on digital marketing remain the catalysts. Management is extremely optimistic about enhancement of customer experience that has aided growth of the cloud segment. Additionally, strategic acquisitions and the resultant synergies are anticipated to prove conducive to growth over the long run.
Furthermore, the company’s move of utilizing other data center operators like Amazon and Alphabet’s geographical reach to expand its international business is commendable and will help it in achieving its targeted $23 billion sales mark by 2022. Nonetheless, stiff competition, currency fluctuations and an increase in investments for international expansions and data centers could negatively impact near-term profitability.
ADP's shares have gained +34.9% over the past year, outperforming the Zacks Outsourcing industry, which has gained +30.6% over the same period. ADP reported strong fourth-quarter fiscal 2018 results, wherein both earnings and revenues surpassed expectations.
The Zacks analyst thinks ADP holds a dominant position in the payroll processing and HCM market, primarily due to its robust product portfolio. Acquisitions have also been a key growth catalyst for the company. Further, the company’s strong balance sheet enables it to continue with its shareholder friendly activities alongside strategic buyouts and investments on product development.
However, ADP faces significant competition in each of its product lines. Failure to meet varying client demands with updated technologies might reduce the demand for its solutions and services, thus hampering its position in the market. Further, the company’s dependence on its payroll, financial, accounting, and other data processing systems remains a concern.
Other noteworthy reports we are featuring today include General Motors and Southwest Airlines.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Pfizer, Salesforce, ADP, General Motors and Southwest Airlines
For Immediate Release
Chicago, IL – September 6, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Pfizer (PFE - Free Report) , Salesforce (CRM - Free Report) , ADP (ADP - Free Report) , General Motors (GM - Free Report) and Southwest Airlines (LUV - Free Report) .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Pfizer, Salesforce and ADP
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer, Salesforce and ADP. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Pfizer’s shares have outperformed the peer group year-to-date (the stock is up +14.2% over this period vs. a +3.8% increase for the Zacks Large-Cap Pharmaceuticals industry). Pfizer has been working on strengthening its product portfolio through acquisitions and licensing deals.
However, Pfizer is facing top-line headwinds in the form of genericization of key drugs, supply challenges in the legacy Hospira portfolio, pricing pressure and rising competition. Nonetheless, the Zacks analyst thinks new products like Ibrance, contribution from acquisitions, cost-cutting efforts, a lower tax rate and share buybacks should help the company achieve its guidance.
Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals through 2022, including around 15 products that have blockbuster potential. Pfizer’s growing immuno-oncology portfolio has strong potential. Bavencio is being considered a key long-term growth driver for Pfizer. In oncology, Pfizer has four potential medicines under FDA’s priority review.
(You can read the full research report on Pfizer here >>>).
Shares of Strong-Buy ranked Salesforce have handily beaten the broader Tech sector over the past year, with the stock up nearly three times the Zacks Technology sector's +20.2% gain. Salesforce reported stellar Q2 results and provided a strong outlook.
The Zacks analyst thinks the company’s diverse cloud offerings and strong spending on digital marketing remain the catalysts. Management is extremely optimistic about enhancement of customer experience that has aided growth of the cloud segment. Additionally, strategic acquisitions and the resultant synergies are anticipated to prove conducive to growth over the long run.
Furthermore, the company’s move of utilizing other data center operators like Amazon and Alphabet’s geographical reach to expand its international business is commendable and will help it in achieving its targeted $23 billion sales mark by 2022. Nonetheless, stiff competition, currency fluctuations and an increase in investments for international expansions and data centers could negatively impact near-term profitability.
(You can read the full research report on Salesforce here >>>).
ADP's shares have gained +34.9% over the past year, outperforming the Zacks Outsourcing industry, which has gained +30.6% over the same period. ADP reported strong fourth-quarter fiscal 2018 results, wherein both earnings and revenues surpassed expectations.
The Zacks analyst thinks ADP holds a dominant position in the payroll processing and HCM market, primarily due to its robust product portfolio. Acquisitions have also been a key growth catalyst for the company. Further, the company’s strong balance sheet enables it to continue with its shareholder friendly activities alongside strategic buyouts and investments on product development.
However, ADP faces significant competition in each of its product lines. Failure to meet varying client demands with updated technologies might reduce the demand for its solutions and services, thus hampering its position in the market. Further, the company’s dependence on its payroll, financial, accounting, and other data processing systems remains a concern.
(You can read the full research report on ADP here >>>).
Other noteworthy reports we are featuring today include General Motors and Southwest Airlines.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.